Mode of Action of Aspirin as a Chemopreventive Agent
- 15 August 2012
- book chapter
- review article
- Published by Springer Science and Business Media LLC
- Vol. 191, 39-65
- https://doi.org/10.1007/978-3-642-30331-9_3
Abstract
Aspirin taken for several years at doses of at least 75 mg daily reduced long-term incidence and mortality due to colorectal cancer. The finding of aspirin benefit at low-doses given once daily, used for cardioprevention, locates the antiplatelet effect of aspirin at the center of its antitumor efficacy. In fact, at low-doses, aspirin acts mainly by an irreversible inactivation of platelet cyclooxygenase (COX)-1 in the presystemic circulation, which translates into a long-lasting inhibition of platelet function. Given the short half-life of aspirin in the human circulation(approximately 20 min) and the capacity of nucleated cells to resynthesize the acetylated COX-isozyme(s), it seems unlikely that a nucleated cell could be the target of aspirin chemoprevention. These findings convincingly suggest that colorectal cancer and atherothrombosis may share a common mechanism of disease, i.e. platelet activation in response to epithelial(in tumorigenesis) and endothelial(in tumorigenesis and atherothrombosis) injury. Activated platelets may also enhance the metastatic potential of cancer cells (through a direct interaction and/or the release of soluble mediators or exosomes) at least in part by inducing the overexpression of COX-2. COX-independent mechanisms of aspirin, such as the inhibition of NF-kB signaling and Wnt/β-catenin signaling and the acetylation of extra-COX proteins, have been suggested to play a role in its chemopreventive effects. However, their relevance remains to be demonstrated in vivo at clinical doses.Keywords
This publication has 105 references indexed in Scilit:
- Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trialsThe Lancet, 2011
- Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trialsThe Lancet, 2010
- Comparison of Cyclooxygenase-1 Crystal Structures: Cross-Talk between Monomers Comprising Cyclooxygenase-1 Homodimers,Biochemistry, 2010
- Eicosanoids and cancerNature Reviews Cancer, 2010
- Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statementThe Lancet Oncology, 2009
- TGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4Cell, 2008
- Regulation of intracellular cyclooxygenase levels by gene transcription and protein degradationProgress in Lipid Research, 2007
- Rapid stimulation of tyrosine phosphorylation signals downstream of G-protein-coupled receptors for thromboxane A2 in human plateletsBiochemical Journal, 2006
- Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancerInternational Journal of Cancer, 2004
- Are there two sides to colorectal cancer?International Journal of Cancer, 2002